Curis, Inc. received written notice from the Nasdaq Stock Market LLC on July 24, 2026, confirming that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule). The company is now in full compliance with the terms set forth by the Nasdaq Hearings Panel. Consequently, Curis will be subject to a Discretionary Panel Monitor for a one-year period starting July 24, 2026. During this monitor period, the company cannot submit a plan of compliance for new deficiencies, and staff cannot grant additional time to regain compliance if requirements are breached. Failure to maintain compliance may result in a delist determination letter and a subsequent hearing. Curis operates in the biotechnology industry, focusing on the development of cancer therapies.

Curis, Inc. implemented a 1-for-20 reverse stock split of its issued and outstanding common stock, effective July 2, 2026, at 5:00 p.m. ET. The split will adjust outstanding warrants, restricted stock units, and stock options, including their corresponding exercise prices. Trading on a reverse split-adjusted basis will commence on July 6, 2026, under the existing ticker symbol CRIS. Curis, Inc. is a biotechnology company focused on developing clinical-stage oncology treatments.

Curis, Inc. announced that its reverse stock split is expected to become effective on July 2, 2026, at 5:00 PM ET. Common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 6, 2026, under the ticker symbol "CRIS" with a new CUSIP number 231269408. The company is a biotechnology firm that develops therapies for cancer.

On June 25, 2026, Curis, Inc. stockholders approved amendments to the Restated Certificate of Incorporation allowing for a reverse stock split. Following this approval, the Board of Directors implemented a 1-for-20 reverse stock split of the company's issued and outstanding common stock. Curis, Inc. is a biotechnology company that develops therapeutics for the treatment of cancer.

Curis, Inc. stockholders approved an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-25, as determined by the Board of Directors. Curis, Inc. is a biotechnology company focused on developing clinical-stage drug candidates for cancer.